Lung cancer remains the most common fatal malignancy, despite more aggressive
therapies. Few patients will survive 5 years, as up to 80% of the patients will present with …

Malignant pleural effusion (MPE) is a common complication in the late stage of malignant
tumors. The appearance of MPE indicates that the primary tumor has spread to the pleura or …

Malignant pleural effusion (MPE) is an exudative effusion with malignant cells. MPE is a
common symptom and accompanying manifestation of metastatic disease. It affects up to …

Rationale: Non–small-cell lung cancer (NSCLC)–associated malignant pleural effusions
(MPEs) are sometimes the only available specimens for molecular analysis. Objectives: This …

Background: Malignant pleural effusion, which is a common clinical problem in patients with
cancer, may be due to both primary thoracic tumours or to a metastatic spread in the chest …

Malignant pleural effusion (MPE) occurring in the patient with lung cancer can have
profound prognostic and management implications. If clinically relevant, such an effusion …

Pleural effusions in patients with malignant disease are not invariably due to metastatic
spread to the pleura and thus, they are not always incurable. For example, about 5% of …

Malignant pleural effusion (MPE) is one of the commonest causes of an exudative pleural
effusion, and its incidence is increasing with increasing cancer prevalence and as more …

Malignant pleural effusion is a common and debilitating complication of advanced malignant
diseases. This problem seems to affect particularly those with lung and breast cancer …

In the era of targeted therapy, the association between lung adenocarcinoma patient
survival and malignant pleural effusions (MPEs) remains unclear. This study investigated the …